NBRV Nabriva Therapeutics AG

Nabriva’s XENLETA Demonstrates High Efficacy in Patients of Advanced Age with Community-Acquired Bacterial Pneumonia (CABP)

Nabriva’s XENLETA Demonstrates High Efficacy in Patients of Advanced Age with Community-Acquired Bacterial Pneumonia (CABP)
EN
13/10/2020

Underlying

NBRVNabriva Therapeutics AG

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Nabriva Therapeutics AG

 PRESS RELEASE
Free
NBRV Nabriva Therape...

Nabriva Therapeutics Provides Corporate Update

Nabriva Therapeutics Provides Corporate Update -Company To Focus on Preserving Cash to Fund Orderly Wind Down of Operations- -Company To Continue Work With Torreya Capital On Asset Monetization- DUBLIN, Ireland, Jan. 06, 2023 (GLOBE NEWSWIRE) -- Nabriva Therapeutics plc (NASDAQ: NBRV) today announced that, after an assessment of strategic options, its Board of Directors approved a plan to preserve cash in order to adequately fund an orderly wind down of the Company’s operations. As previously disclosed, the Company engaged Torreya Capital to facilitate the exploration of a range of str...

January 6, 2023 1 EN
 PRESS RELEASE
Free
NBRV Nabriva Therape...

Nabriva Therapeutics Announces Positive Topline Results from Phase 1 T...

Nabriva Therapeutics Announces Positive Topline Results from Phase 1 Trial of XENLETA® (lefamulin) in Adult Patients with Cystic Fibrosis - PK Data and Safety Profile Consistent with Previous Studies in Healthy Subjects – - Results Support Potential Utility of Lefamulin in Patients with Cystic Fibrosis - DUBLIN, Ireland and FORT WASHINGTON, Pa., Nov. 28, 2022 (GLOBE NEWSWIRE) -- Nabriva Therapeutics plc (NASDAQ: NBRV), a biopharmaceutical company engaged in the commercialization and development of innovative anti-infective agents to treat serious infections, announced positive t...

November 28, 2022 1 EN
 PRESS RELEASE
Free
NBRV Nabriva Therape...

Nabriva Therapeutics Pivoting Strategic Focus Reports Third Quarter Fi...

Nabriva Therapeutics Pivoting Strategic Focus Reports Third Quarter Financial Results and Provides Corporate Update - Shifted Focus to SIVEXTRO to Enable Cost Cutting - - Cash Runway Extended into Q1 2023 - - Q3 2022 Total Revenue of $9.2 Million - - Engaged Torreya Capital As Strategic Advisor - - Conference call today at 4:30 p.m. Eastern Time - DUBLIN, Ireland, Nov. 10, 2022 (GLOBE NEWSWIRE) -- Nabriva Therapeutics plc (NASDAQ: NBRV), a biopharmaceutical company engaged in the commercialization and development of innovative anti-infective agents to treat serious infections, today ...

November 10, 2022 1 EN
 PRESS RELEASE
Free
NBRV Nabriva Therape...

Nabriva Therapeutics to Report Third Quarter 2022 Financial Results an...

Nabriva Therapeutics to Report Third Quarter 2022 Financial Results and Recent Corporate Highlights on November 10, 2022 DUBLIN, Ireland and FORT WASHINGTON, Pa., Nov. 07, 2022 (GLOBE NEWSWIRE) -- Nabriva Therapeutics plc (NASDAQ: NBRV), a biopharmaceutical company engaged in the commercialization and development of innovative anti-infective agents to treat serious infections, today announced that it will report its third quarter financial results along with recent company highlights after the close of the U.S. financial markets on Thursday, November 10, 2022. Nabriva’s management will ho...

November 7, 2022 1 EN
 PRESS RELEASE
Free
NBRV Nabriva Therape...

Nabriva Therapeutics Announces Date of 1-for-25 Reverse Stock Split

Nabriva Therapeutics Announces Date of 1-for-25 Reverse Stock Split DUBLIN, Ireland and FORT WASHINGTON, Pa., Sept. 15, 2022 (GLOBE NEWSWIRE) --  Nabriva Therapeutics plc (NASDAQ: NBRV), a biopharmaceutical company engaged in the commercialization and development of innovative anti-infective agents to treat serious infections, today announced that it will effect a 1-for-25 reverse stock split of its outstanding ordinary shares, which will be effective for trading purposes on the Nasdaq Capital Market as of the commencement of trading on September 16, 2022. At the Annual General Meeting o...

September 15, 2022 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch